Effectiveness and safety of a herbal composition to improve Aging Male Symptoms
Completed
- Conditions
- NA
- Registration Number
- CTRI/2019/02/017506
- Lead Sponsor
- Laila Neutraceuticals Pvt Ltd
- Brief Summary
This proposed study is a randomized, double-blind, placebo-controlled trial, investigating the efficacy and safety of two different doses of LN18178 (200mg, and 400 mg) versus placebo in improving the symptoms of aging in men aged between 36-55 years. The improvement in symptoms will be analysed by the standard scoring system for aging males symptoms and associated serum bio-markers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 120
Inclusion Criteria
- 1.Male subjects aged between 36 and 55 years with a Body Mass Index (BMI) between 22 and 29 kg/m2.
- 2.Subjects with aging males‟ symptoms (AMS) total score between 27 and 43.
- 3.Willingness to walk for 30 min per day (5 days a week) during the course of the study.
- 4.Subjects should have willing partners; considered generally healthy as per health history and routine clinical investigations.
- 5.Ability to understand the risks and benefits of the protocol.
- 6.Subjects who provide written informed consent and agree to be available for regular follow up throughout the study duration.
- 7.Subjects agree to maintain the activity diary.
- 8.Subjects who agree not to start any therapies for sexual health or consuming energy boosting supplements or protein supplements or health drinks during the course of the study.
- 9.Subjects willing to refrain from drinking coffee or caffeinated drinks or beverages during the study.
Exclusion Criteria
- 1.Subjects with history of taking medications for erectile dysfunction, oligospermia or any other sexual problems, urinary & prostate diseases and muscular dystrophy.
- 2.Subjects with clinical history of endocrine disorders e.g. hypopituitarism, pituitary tumors, hypo- and hyper-thyroidism, hypogonadism, inherited (genetic and chromosomal) disorders, etc.
- 3.Subjects diagnosed with sleep apnea or related disorders.
- 4.Subjects consuming medications that can interfere with muscle mass such as corticosteroids, testosterone replacement or anabolic drugs.
- 5.History of psychiatric disorder that may impair the ability of subjects to provide written informed consent.
- 6.Subjects consuming alcohol (>6 standard drinks per week) or smoking.
- 7.Subjects who consume recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or chewable tobacco products.
- 8.Use of any centrally acting anorectic agents, drugs that inhibit the absorption of nutrients and endocannabinoid neuromodulators during the two weeks prior to enrolment into the study is prohibited.
- 9.Subjects having history of Benign Prostate Hyperplasia (BPH), hypertension (BP >130/85 mmHg), diabetes (fasting plasma glucose >125mg/dL) stroke, myocardial infarction, coronary artery disease, cardiac failure, angina, life-threatening arrhythmia within the past 6 months.
- 10.Subjects under medications including anti-hypetensives, inhaled beta agonists, anti-hyperlipidemics, psychotropic etc.
- 11.Subjects who underwent major surgical procedures in last 6 months.
- 12.Subjects with HIV positive or any other STDs. 13.Subject has illness as per the opinion of investigator.
- 14.Subjects participated in a clinical study within the last 90 days prior to recruitment or concurrently participating in another study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Aging males‟ symptoms (AMS) scores from baseline to the end of the study period Baseline, 7th, 14th, 28th, and 56 Days
- Secondary Outcome Measures
Name Time Method Change from baseline to the end of the study period in: 1.Total testosterone
Trial Locations
- Locations (3)
Narayana Hrudayalaya
🇮🇳Bangalore, KARNATAKA, India
Shetty’s Hospital
🇮🇳Bangalore, KARNATAKA, India
Sri Venkateshwara Hospital
🇮🇳Bangalore, KARNATAKA, India
Narayana Hrudayalaya🇮🇳Bangalore, KARNATAKA, IndiaDr Dayanand YaligarPrincipal investigator08071222222alben.sigamani.dr@narayanahealth.org